Locations:

Research

19-NEU-6534-Cohen-stem-cells-for-MS_Hero_650x450

January 17, 2020/Cancer

New BEAT-MS Trial Stages Direct Comparison of Stem Cells and Biologics for Relapsing MS

Knocking out, then restoring, the immune system holds great promise

January 15, 2020/Basic & Translational Science

Low-Dose Chemotherapy Reduces Myeloid-Derived Suppressor Cells in Glioblastoma

Capecitabine-based approach shows promise in a population with few options

thrombolysis of a clot in ischemic stroke

January 6, 2020/Neurosciences/Research

Acute Reperfusion Therapies Are Improving Ischemic Stroke Survival, Database Study Shows

Greatest benefits seen with combined thrombolytic and thrombectomy therapies

19-NEU-5571-lumbar-interbody-fusion-650×450

December 30, 2019/Neurosciences/Research

Fewer Can Be Better: Single-Vendor Purchasing of Spinal Implants Brings Savings While Preserving Outcomes

Single-center retrospective analysis defies conventional wisdom

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

December 7, 2019/Neurosciences/Research

Performing Hemispherectomy in Adulthood Doesn’t Compromise Seizure Freedom Rates

One of the largest series in adults finds outcomes comparable to those in children

7T MRI showing a small focal cortical dysplasia

December 7, 2019/Neurosciences/Research

7T MRI Adds Critical Information for Epilepsy Presurgical Evaluation

Clinically significant lesions detected in nearly half of patients with no lesions on 3T MRI

October 25, 2019/Genomic Medicine

A Genetic Risk Score for Common Epilepsy Types

Largest study of epilepsy genetics identifies polygenic risk score

October 7, 2019/Neurosciences/Research

Obstructive Sleep Apnea: How Do the Leading Therapies Stack Up in Effects on Sleepiness and Blood Pressure?

Retrospective clinic-based study provides intriguing initial comparisons

19-NEU-3979-relapsing-multiple-sclerosis-650×450

September 24, 2019/Neurosciences/Research

Phase 3 Ozanimod Trials Show Good Efficacy and Tolerability at 2 Years for Relapsing MS

Findings hint at potentially easier treatment initiation vs. other S1P receptor modulators

September 18, 2019/Basic & Translational Science

New Myelin Imaging Strategy to Refine MS Diagnosis and Monitoring Garners $1.6M NIH Grant

Benefits of novel PET radiotracer expected to go beyond multiple sclerosis

BackPage 7 of 17Next